Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
106.6 SEK | +2.84% | +7.28% | -15.34% |
Business Summary
Number of employees: 181
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics for Renal Disease Immunoglobulin
90.1
%
| 376 | 46.8 % | 1,087 | 90.1 % | +189.58% |
Outlicensing of Product
6.9
%
| 422 | 52.5 % | 83 | 6.9 % | -80.39% |
Royalty
3.0
%
| 2 | 0.3 % | 37 | 3.0 % | +1,507.26% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
89.1
%
| 372 | 46.4 % | 1,076 | 89.1 % | +189.01% |
Asia
7.6
%
| 287 | 35.7 % | 91 | 7.6 % | -68.10% |
Europe
3.3
%
| 144 | 17.9 % | 40 | 3.3 % | -72.48% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 17-05-17 | |
Director of Finance/CFO | 47 | 17-07-31 | |
Chief Tech/Sci/R&D Officer | 60 | 20-07-23 | |
Chief Tech/Sci/R&D Officer | - | 19-02-28 | |
Chief Tech/Sci/R&D Officer | 65 | 07-03-31 | |
Åsa Hillsten
IRC | Investor Relations Contact | - | 23-03-31 |
Monika Tornsen
PRN | Corporate Officer/Principal | 45 | 01-06 |
Christopher Ngai
PRN | Corporate Officer/Principal | - | 20-03-31 |
Frank Bringstrup
LAW | General Counsel | 65 | 19-01-31 |
Sandra Frithiof
HRO | Human Resources Officer | 49 | 22-07-10 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 23-05-29 |
Henrik Stenqvist
BRD | Director/Board Member | 57 | 21-12-31 |
Elmar Schnee
CHM | Chairman | 65 | 19-05-07 |
Hilde Furberg
BRD | Director/Board Member | 65 | 14-08-31 |
Director/Board Member | 63 | 21-12-31 | |
Diane Parks
BRD | Director/Board Member | 72 | 19-05-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 59,580,087 | 43,663,885 ( 73.29 %) | 5,908,018 ( 9.916 %) | 73.29 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
5,908,018 | 9.92% | 62,657,308 $ |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.34% | 508M | |
+3.82% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |
- Stock Market
- Equities
- CALTX Stock
- Company Calliditas Therapeutics AB